At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Tenalisibdrug
Likely dose
Tenalisib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
In Brief
A Phase 2 clinical trial evaluating Tenalisib for Leukemia, Lymphocytic, Chronic, B-Cell. Completed, enrolled 21 participants across 6 sites in 3 countries.
Detailed Summary
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphocytic, Chronic, B-Cell
CountriesBulgaria, Georgia, Poland
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartNov 2019
First PostedDec 2019
Primary CompletionOct 2020
TodayJul 2026
First PostedDec 18, 2019
Enrollment StartNov 28, 2019
Primary CompletionOct 2, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.5 years ago
Interventions
Tenalisibdrug
Tenalisib 800 mg BID, Orally